Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 401–500 of 1,001
Vora, J. P., Cherney, D. Z. I., Kosiborod, M., Spaak, J., Kanumilli, N., Khunti, K., Lam, C. S. P., Bachmann, M., Fenici, P., & the CaReMe Global Alliance (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15485 · Cited by 32
“11,84,85 In one study, a subgroup analysis of diabetic patients demonstrated greater absolute risk reduction with dual antiplatelet therapy in patients with diabetes versus those without (1.5% vs. 1.1%), possibly reflecting the higher baseline risk of CV death, MI or stroke in the former group.”
InfluentialHarada, Y., Michel, J., Lohaus, R., Mayer, K., Emmer, R., Lahmann, A. L., Colleran, R., Giacoppo, D., Wolk, A., ten Berg, J. M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-02-0101 · Cited by 28
“On the other hand, the DAPT trial showed that prolonged therapy beyond 12 months reduced myocardial infarction and very late stent thrombosis but increased the risk of moderate or severe bleeding, compared with 12 months DAPT (4).”
BackgroundMethodFox, K. A. A., Eikelboom, J. W., Anand, S. S., Bhatt, D. L., Bosch, J., Connolly, S. J., Harrington, R. A., Steg, P. G., & Yusuf, S. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy347 · Cited by 29
Self-citationMisumida, N., Abo-Aly, M. A., Kim, S. M., Ogunbayo, G. O., Abdel‐Latif, A., & Ziada, K. M. (2018) · Clinical Cardiology · doi:10.1002/clc.23075 · Cited by 28
Palmerini, T., Bruno, A. G., Gilard, M., Morice, M., Valgimigli, M., Montalescot, G., Collet, J., Riva, D. D., Reggiani, M. L. B., Steg, P. G., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007541 · Cited by 28
Self-citationPlatelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
Camilli, M., Iannaccone, G., Vecchia, G. L., Cappannoli, L., Scacciavillani, R., Minotti, G., Massetti, M., Crea, F., & Aspromonte, N. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1943353 · Cited by 31
Gaudino, M. F. L., Audisio, K., Hueb, W. A., Stone, G. W., Farkouh, M. E., Franco, A. D., Rahouma, M., Serruys, P. W. J. C., Bhatt, D. L., Biondi‐Zoccai, G., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.06.003 · Cited by 30
Costa, F., Adamo, M., Ariotti, S., Navarese, E. P., Biondi‐Zoccai, G., & Valgimigli, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.058 · Cited by 28
Chang, T. I., Montez‐Rath, M. E., Tsai, T. T., Hlatky, M. A., & Winkelmayer, W. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.104 · Cited by 28
Genotoxicity and Carcinogenicity Testing of Pharmaceuticals
Graziano, M. J., & Jacobson‐Kram, D. (2015) · Springer eBooks · doi:10.1007/978-3-319-22084-0 · Cited by 28
Gargiulo, G., Santucci, A., Piccolo, R., Franzone, A., Ariotti, S., Baldo, A., Esposito, G., Moschovitis, A., Windecker, S., & Valgimigli, M. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26921 · Cited by 28
“On the other hand, a recent trial on DAPT duration has shown a relevant reduction in rates of stent thrombosis (ST) and myocardial infarction (MI) in patients free from bleeding or ischemic events in the 30-month versus 12-month DAPT duration groups [13].”
BackgroundRudolph, T. K., Fuchs, A., Klinke, A., Schlichting, A., Friedrichs, K. P., Hellmich, M., Mollenhauer, M., Schwedhelm, E., Baldus, S. E., & Rudolph, V. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.099 · Cited by 28
Challenges in secondary prevention after acute myocardial infarction: A call for action
Piepoli, M. F., Corrà, U., Dendale, P., Frederix, I., Prescott, E., Schmid, J. P., Cupples, M., Deaton, C., Doherty, P., Giannuzzi, P., et al. (2017) · European Journal of Cardiovascular Nursing · doi:10.1177/1474515117702594 · Cited by 34
Giubilato, S., Lucà, F., Abrignani, M. G., Gatto, L., Rao, C. M., Ingianni, N., Amico, F., Rossini, R., Caretta, G., Cornara, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185989 · Cited by 33
Oral dual antiplatelet therapy: what have we learnt from recent trials?
Montalescot, G., & Sabatine, M. S. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv377 · Cited by 27
What about the risk of thrombosis with bioresorbable scaffolds?
Capodanno, D., Joner, M., & Zimarino, M. (2015) · EuroIntervention · doi:10.4244/eijv11sva43 · Cited by 27
Giustino, G., Harari, R., Baber, U., Sartori, S., Stone, G. W., Leon, M. B., Windecker, S., Serruys, P. W. J. C., Kastrati, A., von Birgelen, C., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1978 · Cited by 27
Self-citationGuedeney, P., & Collet, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113474 · Cited by 32
“Since the landmark PLATO and therapeutic outcomes by optimizing platelet inhibition with Prasugrel-thrombolysis in myocardial infarction 38 (TRITON-TIMI 38) trials, use of DAPT based on the association of aspirin with a potent P2Y12 receptors inhibitors (i.e., ticagrelor or prasugrel) has been the cornerstone of the a…”
BackgroundInfluentialDiseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies
Thomas, A. W., Gitto, M., Shah, S., Saito, Y., Tîrziu, D., Chieffo, A., Stefanini, G. G., & Lansky, A. J. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.100607 · Cited by 30
Sex and Racial Disparities in Peripheral Artery Disease
Divakaran, S., Krawisz, A. K., Secemsky, E. A., & Kant, S. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319399 · Cited by 27
Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury
McDonald, A. I., & Iruela‐Arispe, M. L. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.06.007 · Cited by 27
Sawaya, F., Morice, M., Spaziano, M., Mehran, R., Didier, R. J., Roy, A. K., Valgimigli, M., Kim, H.-S., Park, K. W., Hong, M., et al. (2016) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26653 · Cited by 27
“Our report, does not address whether continuing DAPT beyond 1-year might decreases ischemic outcomes in men and women as evaluated by the DAPT trial [2,40], though other studies in populations of patients with prior acute coronary syndromes do suggest benefit that is not sex-dependent [4,23].”
BackgroundClinical and economic outcomes among elderly myocardial infarction survivors in the United States
Yang, E., Stokes, M., Johansson, S., Mellström, C., Magnuson, E. A., Cohen, D. J., & Hunt, P. R. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12222 · Cited by 27
“guidelines do not directly address this chronic phase of disease [2-4] and yet recent trials found that dual antiplatelet therapy continued beyond the first year after acute MI lowers the risk of cardiovascular death, MI, and stroke [5, 6].”
ResultSelf-citationChen, Y.-T., Chen, H., Hsu, C., Chao, P.-W., Kuo, S., Ou, S., & Shih, C.-J. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04430416 · Cited by 27
Guimarães, P. O., Zakroysky, P., Goyal, A., Lópes, R. D., Kaltenbach, L. A., & Wang, T. Y. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.09.031 · Cited by 27
La relación bidireccional entre el cáncer y la ateroesclerosis
Raposeiras‐Roubín, S., & Cordero, A. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.011 · Cited by 28
Lindholm, D. P., Sarno, G., Erlinge, D., Svennblad, B., Hasvold, L. P., Janzon, M., Jernberg, T., & James, S. K. (2019) · Heart · doi:10.1136/heartjnl-2018-314590 · Cited by 32
Ferreira, R. L. S., dos Anjos, M. A. S., Ledesma, E. F., Pereira, J. E. S., & Nóbrega, A. K. C. (2020) · Materiales de Construcción · doi:10.3989/mc.2020.02819 · Cited by 33
Delvoye, F., Maïer, B., Escalard, S., Labreuche, J., Thion, L.-A., Aknouche, S., Hébert, S., Redjem, H., Smajda, S., Cicciò, G., et al. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105521 · Cited by 27
Intelligent Platelet Morphometry
Zhou, Y., Isozaki, A., Yasumoto, A., Xiao, T., Yatomi, Y., Lei, C., & Goda, K. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.12.012 · Cited by 29
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike
Franchi, F., Rollini, F., Park, Y., & Angiolillo, D. J. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.009 · Cited by 27
“Importantly, the higher risk of ST and recurrent MI observed during the 3 months following discontinuation of thienopyridine treatment, was likely attributed to a withdrawal of protection [60].”
BackgroundMethodInfluentialAntiplatelet Management for Coronary Heart Disease: Advances and Challenges
Gillette, M., Morneau, K. M., Hoang, V., Virani, S. S., & Jneid, H. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0581-6 · Cited by 28
Furtado, R. H. D. M., Giugliano, R. P., Strunz, C. M. C., Filho, C. C., Ramires, J. A. F., Filho, R. K., Lemos, P. A., Pereira, A. C., Rocha, T. R., Freire, B. T., et al. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0172-5 · Cited by 27
“We must stress that, although patients with remote PCI or MI are not widely being given DAPT following current guidelines, there is a trend in the medical literature to extend the use of ADP receptor blockers beyond the first year after the intervention or MI, based on new evidence from large randomized studies [40, 4…”
BackgroundFranzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Hamm, C. W., Steg, P. G., Heg, D., Branca, M., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-20-00145 · Cited by 26
Self-citationRivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting
Matoba, T., Yasuda, S., Kaikita, K., Akao, M., Ako, J., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.07.045 · Cited by 26
Laborante, R., Borovac, J. A., Galli, M., Rodolico, D., Ciliberti, G., Restivo, A., Cappannoli, L., Arcudi, A., Vergallo, R., Zito, A., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1009475 · Cited by 28
“Another strategy to reduce ischemic recurrences in patients at high ischemic risk, particularly those with prior AMI, is represented by prolongation of DAPT duration beyond 1 year.”
BackgroundMethodInfluentialAbbreviated or Standard Antiplatelet Therapy in HBR Patients
Landi, A., Heg, D., Frigoli, E., Vranckx, P., Windecker, S., Siegrist, P. T., Cayla, G., Włodarczak, A., Cook, S., Gómez‐Blázquez, I., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.01.366 · Cited by 28
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies
Costa, F., Windecker, S., & Valgimigli, M. (2017) · Drugs · doi:10.1007/s40265-017-0806-1 · Cited by 26
“The population of the DAPT trial was highly selected due to the initial run-in phase of the study, which excluded almost 50% of the initially screened population [5].”
InfluentialDrug-Eluting or Bare-Metal Stents for Coronary Artery Disease
Urban, P., Oldroyd, K. G., & Krackhardt, F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1613866 · Cited by 26
Kwesiga, M. P., Gillette, A. A., Razaviamri, F., Plank, M. E., Canull, A. L., Alesch, Z., He, W., Lee, B. P., & Guillory, R. J. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.10.017 · Cited by 25
“(PCI) with a bare metal or drug eluting stent [2,3] which has limitations that include acute thrombotic events, hypersensitivity to the drug eluting polymer coating, neointima response from inflammatory reactions, and stent fracture [4,5].”
BackgroundCurrent Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review
Galanti, K., Marino, M. D., Mansour, D., Testa, S., Rossi, D., Scollo, C., Magnano, R., Pezzi, L., D’Alleva, A., Forlani, D., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2508281 · Cited by 27
“[30,32,33]), along with therapeutic regimens, drug indications, and re-4 spective recommendation classes according to ESC guidelines.”
BackgroundMoschonas, I. C., Goudevenos, J. A., & Tselepis, A. D. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.049 · Cited by 25
Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
Goli, R. R., Contractor, M. M., Nathan, A. S., Tuteja, S., Kobayashi, T., & Giri, J. S. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0698-2 · Cited by 28
Mauri, L., Kirtane, A. J., Windecker, S., Yeh, R. W., Dauerman, H. L., Price, M. J., Christen, T., Allocco, D. J., Meredith, I. T., & Kereiakes, D. J. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.004 · Cited by 25
Self-citationLuca, L. D., Piscione, F., Colivicchi, F., Lucci, D., Mascia, F., Marinoni, B., Cirillo, P. L., Grosseto, D., Mauro, C., Calabrò, P., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.055 · Cited by 25
Miura, K., Shimada, T., Ohya, M., Murai, R., Amano, H., Kubo, S., Tada, T., Tanaka, H., Fuku, Y., Goto, T., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0395 · Cited by 25
“(3) The ARC-HBR criteria were associated with long-term bleeding events up to 8 years.”
BackgroundValidation of the 4‐Item PRECISE‐DAPT Score: A SWEDEHEART Study
Wester, A., Mohammad, M. A., Olivecrona, G. K., Holmqvist, J., Yndigegn, T., & Koul, S. M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.020974 · Cited by 27
Optimal Duration of Dual Antiplatelet Therapy After DES Implantation
Verdoia, M., Schaffer, A., Barbieri, L., Montalescot, G., Collet, J., Colombo, A., Suryapranata, H., & Luca, G. D. (2015) · Angiology · doi:10.1177/0003319715586500 · Cited by 27
“In 4 trials, new P2Y12 inhibitors (prasugrel and ticagrelor) were also used in a group of patients.(12,13,19,20) In 1 trial, clopidogrel was administered at the dose of 150 mg daily in patients with 2209 records iden fied by li erature search”
BackgroundMethodProlonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials
Cassese, S., Byrne, R. A., Ndrepepa, G., Schunkert, H., Fusaro, M., & Kastrati, A. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0860-1 · Cited by 25
“Major bleeding was most frequently adjudicated according to Thrombolysis in Myocardial Infarction criteria [22] with four trials [7, 16, 18, 20] presenting the incidence of bleeding also according to ARC criteria [23].”
BackgroundMethodResultInfluentialTarantini, G., Fovino, L. N., Tellaroli, P., Chieffo, A., Barioli, A., Menozzi, A., Frasheri, A., Garbo, R., Masotti-Centol, M., Salvatella, N., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.068 · Cited by 25
“In the recent DAPT trial [11] although patients' selection and DAPT duration were different from our study, DM patients treated by first and second-generation DES did not seem to gain any benefit from prolonged (N12-month) DAPT in terms of MACE reduction, because of increased bleeding complications.”
ResultCosta, F., Ariotti, S., Valgimigli, M., Kolh, P. H., & Windecker, S. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-015-9632-6 · Cited by 25
“counterbalanced by higher bleeding rates [35, 36].”
Dovizio, M., Sacco, A., & Patrignani, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.003 · Cited by 25
Broeg-Morvay, A., Mordasini, P., Slezak, A., Liesirova, K., Meisterernst, J., Schroth, G., Arnold, M., Jung, S., Mattle, H. P., Gralla, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170045 · Cited by 25
Can Functional Testing for Ischemia and Viability Guide Revascularization?
Mielniczuk, L. M., Tóth, G. G., Xie, J. X., Bruyne, B. D., Shaw, L. J., & Beanlands, R. S. (2017) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2016.12.011 · Cited by 25
Sharma, A., Agrawal, S., Garg, A., Vallakati, A., Lavie, C. J., & Helft, G. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27123 · Cited by 25
Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration
Lugo‐Gavidia, L. M., & Ferreiro, J. L. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.03.001 · Cited by 25
Arahata, M., & Asakura, H. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s174896 · Cited by 26
Extended Duration Dual Antiplatelet Therapy and Mortality: A Systematic Review and Meta-Analysis
Elmariah, S., Mauri, L., & Doros, G. D. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.09.011 · Cited by 24
Self-citationNorth American Thrombosis Forum, AF Action Initiative Consensus Document
Ruff, C. T., Ansell, J., Becker, R. C., Benjamin, E. J., Deicicchi, D. J., Estes, N. A. M., Ezekowitz, M. D., Fanikos, J. R., Fareed, J., Garcia, D. A., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.001 · Cited by 24
“Last, clinicians who previously may have been comfortable with a strategy of warfarin plus clopidogrel in stented patients with AF (or another indication for anticoagulant therapy) may have a change of heart, thus favoring DAPT and, as a result, overlooking its well-documented inferiority to oral anticoagulant therapy…”
BackgroundSteg, P. G., & Bhatt, D. L. (2015) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872615610868 · Cited by 24
Self-citationSchiele, F., Puymirat, É., Ferrières, J., Simon, T., Fox, K. A. A., Eikelboom, J. W., & Danchin, N. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.138 · Cited by 24
“, International Journal of Cardiology, https://doi events, an excess of hemorrhagic complications was observed in the extended DAPT arm [33].”
BackgroundHuseynov, A., Reinhardt, J., Chandra, L., Dürschmied, D., & Langer, H. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076280 · Cited by 26
“DAPT 2014 DAPT over 12 months after PCI reduces cardiovascular events but increases bleeding complications [97]”
BackgroundCapodanno, D., Lip, G. Y. H., Windecker, S., Huber, K., Kirchhof, P. F., Boriani, G., Lane, D. A., Gilard, M., Collet, J., Valgimigli, M., et al. (2015) · EuroIntervention · doi:10.4244/eijv10i9a174 · Cited by 24
Fosbøl, E. L., Ju, C., Anstrom, K. J., Zettler, M. E., Messenger, J. C., Waksman, R., Effron, M. B., Baker, B., Cohen, D. J., Peterson, E. D., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.003602 · Cited by 24
Self-citationPatti, G., Cavallari, I., Antonucci, E., Calabrò, P., Cirillo, P. L., Gresele, P., Palareti, G., Pengo, V., Pignatelli, P., Ricottini, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186961 · Cited by 24
Greco, A., Capodanno, D., & Angiolillo, D. J. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676612 · Cited by 24
Khan, M. S., Memon, M. M., Usman, M., Alnaimat, S., Khan, S. U., Khan, A. R., Yamani, N., Fugar, S. S., Mookadam, F., Krasuski, R. A., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00337-5 · Cited by 24
Bioresorbable Drug-Eluting Stents
Byrne, R. A., & Kastrati, A. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.11.010 · Cited by 24
“antiplatelet therapy for patients treated with bioresorbable stents remains unclear (13,14).”
BackgroundTailakh, M. A., Friger, M. D., Zahger, D., Sidi, A., Mazor-Dray, E., & Novack, V. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.09.007 · Cited by 23
Verdoia, M., Khedi, E., Ceccon, C., Suryapranata, H., & Luca, G. D. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.02.095 · Cited by 23
Sumaya, W., Geisler, T., Kristensen, S. D., & Storey, R. F. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679903 · Cited by 23
Eurasian Guidelines for the diagnostics and management of stable coronary artery disease (2020-2021)
IuA, K., Барбараш, О. Л., Boshchenko, A. A., Кашталап, В. В., Kukharchuk, V. V., Миронов, В. М., Панченко, Е. П., Ruda, M. M., Samko, A. N., Соболева, Г. Н., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-3-54-93 · Cited by 23
Ullah, W., Zahid, S., Sandhyavenu, H., Faisaluddin, M., Khalil, F. M., Pasha, A. K., Alraies, M. C., Cuisset, T., Rao, S. V., Sabouret, P. F., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac020 · Cited by 23
Kinlay, S., Young, M., Sherrod, R., & GAGNON, D. R. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027055 · Cited by 24
Greco, A., Finocchiaro, S., Angiolillo, D. J., & Capodanno, D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2171788 · Cited by 23
Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs
Ford, I. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615588085 · Cited by 26
Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
Baaten, C. C. F. M. J., Veenstra, L. F., Wetzels, R. J. H., van Geffen, J. P., Swieringa, F., Witt, S., Henskens, Y., Crijns, H. J. G. M., Nylander, S., van Giezen, J. J. J., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.122457 · Cited by 23
Camaro, C., Damen, S. A. J., Brouwer, M. A., Kedhi, E., Lee, S. W., Verdoia, M., Barbieri, L., Rognoni, A., Hof, A. W. J. V. ’., Ligtenberg, E., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.04.016 · Cited by 23
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease
Welsh, R. C., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., Bode, C., Gibson, C. M., & Ohman, E. M. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.08.008 · Cited by 23
“04% over the subsequent 1 to 2 years which has a modest reduced with clopidogrel monotherapy or DAPT.(13,18,19) In these same trials, ASA monotherapy”
BackgroundMethodInfluentialSelf-citationSchmidt, A. C. S., Kereiakes, D. J., Cutlip, D. E., Yeh, R. W., D’Agostino, R. B., Massaro, J. M., Hsieh, W.-H., & Mauri, L. (2017) · Circulation · doi:10.1161/circulationaha.116.024835 · Cited by 25
Self-citationSiasos, G., Skotsimara, G., Oikonomou, E. K., Sagris, Μ., Mystakidi, V. C., Bletsa, E., Stampouloglou, P. K., Theofilis, P., Charalampous, G., & Tousoulis, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200417145605 · Cited by 23
Fujii, T., & Ikari, Y. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0806 · Cited by 23
Soldati, S., Martino, M. D., Rosa, A. C., Fusco, D., Davoli, M., & Mureddu, G. F. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02261-6 · Cited by 24
Piccolo, R., Feres, F., Abizaid, A., Gilard, M., Morice, M., Hong, M., Kim, H.-S., Colombo, A., Bhatt, D. L., Palmerini, T., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.06.001 · Cited by 23
Malapposition: is it a major cause of stent thrombosis?
Mori, H., Joner, M., Finn, A. V., & Virmani, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw006 · Cited by 23
Savarese, G., Savonitto, S., Lund, L. H., Paolillo, S., Marciano, C., Dellegrottaglie, S., Parente, A., Trimarco, B., Lüscher, T. F., & Filardi, P. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw011 · Cited by 22
Antithrombotic Therapy in Peripheral Artery Disease
Jones, W. S., & Patel, M. R. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.021 · Cited by 22
Zhu, P., Tang, X., Song, Y., Zhang, Y., Gao, L., Gao, Z., Chen, J., Yang, Y., Gao, R.-L., Xu, B., et al. (2020) · Platelets · doi:10.1080/09537104.2020.1802412 · Cited by 22
“Furthermore, the optimal duration of DAPT is still under debate, previous studies failed to show a clear benefit of prolonged DAPT in patients with diabetes [21,22].”
BackgroundFactors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial
Cho, J. Y., Lee, S., Yun, K. H., Kim, B., Hong, S., Ko, J. S., Rhee, S. J., Oh, S. K., Shin, D., Ahn, C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019630 · Cited by 23
“1,2,25 In addition, the radial or femoral access for PCI should be determined, taking into account patients’ characteristics, clinical situations, and lesional complexities, as well as the risk of bleeding.”
Current management and prognosis of patients with recurrent myocardial infarction
Luca, L. D., Paolucci, L., Nusca, A., Putini, R. L., Mangiacapra, F., Natale, E., Ussia, G. P., Colivicchi, F., Grigioni, F., Musumeci, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203080 · Cited by 23
Ziada, K. M., Abdel‐Latif, A., Charnigo, R. J., & Moliterno, D. J. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26110 · Cited by 22
Ueda, H., Kido, A., Matsuhisa, S., Asawa, K., Yoshida, N., Tsujimoto, M., Sasaki, Y., Kuga, Y., Yamasaki, M., Ueda, K., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.014 · Cited by 22
“However, several studies demonstrated extended treatment with aspirin and a P2Y12 inhibitor beyond 1 year after coronary stenting was associated with reduction in the rate of major adverse cardiovascular and cerebrovascular events and increase in the rate of bleeding events (12,13).”
BackgroundSimon, N., Finzi, J., Cayla, G., Montalescot, G., Collet, J., & Hulot, J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1882-3 · Cited by 22
Antiplatelet Therapy and Spontaneous Retroperitoneal Hematoma: A Case Report and Literature Review
Ibrahim, W., Mohamed, A., Sheikh, M., Shokr, M., Hassan, A., Wienberger, J., & Afonso, L. (2017) · American Journal of Case Reports · doi:10.12659/ajcr.901622 · Cited by 22
“Evidence suggests that continuing dual antiplatelet therapy beyond one year after DES PCI reduces the risk of major adverse cardiac events [8].”
BackgroundPolymer-free sirolimus-eluting stents in a large-scale all-comers population
Krackhardt, F., Kočka, V., Waliszewski, M. W., Utech, A., Lustermann, M., Hudec, M., Studenčan, M., Schwefer, M., Yu, J., Jeong, M. H., et al. (2017) · Open Heart · doi:10.1136/openhrt-2017-000592 · Cited by 22
Nanoparticle-Mediated Cell Capture Enables Rapid Endothelialization of a Novel Bare Metal Stent
Tefft, B. J., Uthamaraj, S., Harbuzariu, A., Harburn, J. J., Witt, T. A., Newman, B., Psaltis, P. J., Hlinomaz, O., Holmes, D. R., Gulati, R., et al. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0404 · Cited by 22
Self-citationTantry, U. S., Navarese, E. P., Myat, A., Chaudhary, R., & Gurbel, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1457649 · Cited by 23
“plays an important role in these cessation-related ischemic event occurrences even at 33 months post-stenting for the index event [31].”
BackgroundLee, S. W. L., Tam, F. C. C., Chan, K. K. W., Lam, S. C. C., Kong, S., Shea, C., Wong, M. K. L., Wong, Y. T. A., Yung, A. S. Y., Zhang, L., et al. (2018) · EuroIntervention · doi:10.4244/eij-d-18-00061 · Cited by 22
Neupane, S., Khawaja, O. A., Edla, S., Singh, H., Othman, H., Bossone, E., Yamasaki, H., Rosman, H., Eggebrecht, H., & Mehta, R. H. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28045 · Cited by 24
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.